- AustraliaNorth AmericaWorld
Investing News NetworkYour trusted source for investing success
- Lithium Outlook
- Oil and Gas Outlook
- Gold Outlook Report
- Uranium Outlook
- Rare Earths Outlook
- All Outlook Reports
- Top Generative AI Stocks
- Top EV Stocks
- Biggest AI Companies
- Biggest Blockchain Stocks
- Biggest Cryptocurrency-mining Stocks
- Biggest Cybersecurity Companies
- Biggest Robotics Companies
- Biggest Social Media Companies
- Biggest Technology ETFs
- Artificial Intellgience ETFs
- Robotics ETFs
- Canadian Cryptocurrency ETFs
- Artificial Intelligence Outlook
- EV Outlook
- Cleantech Outlook
- Crypto Outlook
- Tech Outlook
- All Market Outlook Reports
- Cannabis Weekly Round-Up
- Top Alzheimer's Treatment Stocks
- Top Biotech Stocks
- Top Plant-based Food Stocks
- Biggest Cannabis Stocks
- Biggest Pharma Stocks
- Longevity Stocks to Watch
- Psychedelics Stocks to Watch
- Top Cobalt Stocks
- Small Biotech ETFs to Watch
- Top Life Science ETFs
- Biggest Pharmaceutical ETFs
- Life Science Outlook
- Biotech Outlook
- Cannabis Outlook
- Pharma Outlook
- Psychedelics Outlook
- All Market Outlook Reports
Actinium Announces Submission of IND For Actimab-A in Combination with CLAG-M
Actinium Pharmaceuticals (NYSE:ATNM) announced that an Investigational New Drug application has been submitted with the U.S. Food and Drug Administration (FDA) for Actimab-A in combination with CLAG-M for relapsed or refractory Acute Myeloid Leukemia patients. As quoted in the press release: Dr. Mark Berger, Actinium’s Chief Medical Officer said, “CLAG-M has become a widely used regimen …
Actinium Pharmaceuticals (NYSE:ATNM)announced that an Investigational New Drug application has been submitted with the U.S. Food and Drug Administration (FDA) for Actimab-A in combination with CLAG-M for relapsed or refractory Acute Myeloid Leukemia patients.
As quoted in the press release:
Dr. Mark Berger, Actinium’s Chief Medical Officer said, “CLAG-M has become a widely used regimen for patients that is the standard of care at many institutions across the U.S. based on its ability to produce remissions in patients in relapse. By utilizing Actimab-A with CLAG-M, we expect to leverage Actimab-A’s potency and minimal extramedullary toxicities to derive synergies when used in combination with other active AML drugs. This important Phase 1 study will assess safety of the combination and determine an appropriate dose level for future studies. In future studies, we believe that this exciting combination could increase remission rates in relapsed patients. We also expect to use the Actimab-A CLAG-M combination regimen to increase the rate of successful stem cell transplant in relapsed patients, via improved myeloablation with the combination regimen. We look forward to work with Dr. Atallah and his colleagues at the Medical College of Wisconsin.”
Latest News
Investing News Network websites or approved third-party tools use cookies. Please refer to the cookie policy for collected data, privacy and GDPR compliance. By continuing to browse the site, you agree to our use of cookies.